ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2418

Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data

Naonobu Sugiyama M.D., Ph.D1, Tatsunori Murata, M.S.2, Yosuke Morishima3, Yuri Fukuma4, Yoshiyuki Shibasaki4 and Lisa Marshall5, 1Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 2Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, 3RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 4Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 5Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, etanercept and rheumatoid arthritis (RA), Japanese

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose

Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but the impact of their high drug costs on medical expenditure remains a concern. The aim of this study is to characterize the treatment patterns of patients with RA treated with biologics and evaluate the direct biologics cost and medical cost using Japanese claims data provided by Japan Medical Data Center Co., Ltd.

Methods

Patients with RA (defined by ICD10 code) treated with ETN, IFX, ADA, and TCZ between Jan, 2005 and Mar, 2013 were included.  Annual costs of the biologics per patient, based on average daily dose and NHI drug price, were calculated from 2009 to 2012 for ETN, IFX, ADA, and TCZ. Patients were grouped based upon their initial prescription for either ETN, IFX, ADA, or TCZ. One year biologics cost including all biologics (including second or more, e.g. golimumab) and total medical cost following initial prescription were compared between ETN and the other treatment groups. Discontinuation and switching event rates to other biologics in each group were estimated using Kaplan-Meier survival analysis. Dose changes, based on +/-50% change in average dose per administration, at 3 month intervals were also evaluated up to 4 years following initial prescription.

Results

A total of 524 patients were identified for longitudinal analysis, with 45% (n=238) initiating ETN, 41% (n=217) initiating TFX, and 13% (n=69) initiating. The cross-sectional annual biologics cost was $8,000 in 2009 and $7,200 in 2012 in patients with ETN, $10,000 both in 2009 and in 2012 in patients with ADA, $12,000 in 2009 and $16,000 in 2012 in patients with IFX, $9,000 in 2009 and $8,000 in 2012 in patients with TCZ (Fig.1). The one year total medical costs from the initial prescription in ETN, IFX and ADA groups were approximately $19,000, $26,000 and $23,000, respectively (ETN: IFX p<0.001, ETN: ADA p<0.001). A similar trend was also observed in the biologics cost. The discontinuation event rates at 36 months was 48.6%, 58.0% and 75.8% in ETN, IFX and ADA group, respectively (ETN: IFX p=0.052, ETN: ADA p=0.004) (Fig.2). The switching event rate to other biologics at 36 months was 9.9%, 17.4% and 27.7% in ETN, IFX and ADA group, respectively (ETN: IFX p=0.042 , ETN: ADA p=0.052) (Fig.3). The longitudinal dose changing trend in IFX was different from ETN and ADA group.

Conclusion

The biologic and total medical costs, along with discontinuation and switching event rates were lowest in ETN group. Although there are limitations such as channeling bias, these findings might imply the clinical cost reductive benefits in ETN first line treated group.


Disclosure:

N. Sugiyama M.D., Ph.D,

Pfizer Inc,

3;

T. Murata, M.S.,

Pfizer Inc,

5;

Y. Morishima,

Pfizer Inc,

3;

Y. Fukuma,

Pfizer Inc,

3;

Y. Shibasaki,

Pfizer Inc,

3;

L. Marshall,

Pfizer Inc,

3.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-pattern-and-direct-cost-of-biologics-for-rheumatoid-arthritis-patients-a-real-world-analysis-of-nationwide-japanese-claims-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.